- Home
- JZXN vs SLRX Comparison
JZXN vs SLRX Comparison
Compare JZXN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- SLRX
- Stock Information
- Founded
- JZXN 2019
- SLRX N/A
- Country
- JZXN China
- SLRX United States
- Employees
- JZXN N/A
- SLRX N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- SLRX Health Care
- Exchange
- JZXN Nasdaq
- SLRX Nasdaq
- Market Cap
- JZXN 51.8M
- SLRX 2.9M
- IPO Year
- JZXN 2021
- SLRX N/A
- Fundamental
- Price
- JZXN $1.03
- SLRX $5.29
- Analyst Decision
- JZXN
- SLRX
- Analyst Count
- JZXN 0
- SLRX 0
- Target Price
- JZXN N/A
- SLRX N/A
- AVG Volume (30 Days)
- JZXN 256.3K
- SLRX 129.6K
- Earning Date
- JZXN 03-05-2026
- SLRX 08-12-2025
- Dividend Yield
- JZXN N/A
- SLRX N/A
- EPS Growth
- JZXN N/A
- SLRX N/A
- EPS
- JZXN N/A
- SLRX N/A
- Revenue
- JZXN $97,465.00
- SLRX N/A
- Revenue This Year
- JZXN N/A
- SLRX N/A
- Revenue Next Year
- JZXN N/A
- SLRX N/A
- P/E Ratio
- JZXN N/A
- SLRX N/A
- Revenue Growth
- JZXN N/A
- SLRX N/A
- 52 Week Low
- JZXN $0.78
- SLRX $4.50
- 52 Week High
- JZXN $7.82
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- JZXN 58.00
- SLRX 39.91
- Support Level
- JZXN $0.78
- SLRX $4.50
- Resistance Level
- JZXN $1.12
- SLRX $5.65
- Average True Range (ATR)
- JZXN 0.07
- SLRX 0.40
- MACD
- JZXN 0.04
- SLRX 0.18
- Stochastic Oscillator
- JZXN 73.53
- SLRX 44.38
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.